NCT06567782 2026-03-12
AZUR-4
GlaxoSmithKline
Phase 2 Recruiting
Clinical Trials
14 trialsNCT06830239 2026-02-12
Superhero
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT07381777 2026-02-02
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT04165772 2026-01-23
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05723562 2026-01-08
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT06640049 2025-11-17
China AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT05239546 2025-05-25
NAIO
University of Iowa
Phase 2 Recruiting
NCT06757244 2025-03-18
DOVIPA
Hopital Foch
Phase 2 Recruiting
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT06059495 2024-02-05
DEWI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn